Cassava Sciences shares fall after SEC charges for misleading Alzheimer’s drug trial claims
WASHINGTON (Reuters) -Shares of Cassava Sciences (NASDAQ:SAVA) fell 10% in post-market trading on Thursday after the U.S. Securities and Exchange Commission charged the biopharmaceutical company and two former executives for…
